LUNDEMOSE ANKER MD, PH.D, DSC 4
4 · OSI PHARMACEUTICALS INC · Filed Dec 18, 2009
Insider Transaction Report
Form 4
LUNDEMOSE ANKER MD, PH.D, DSC
Exec. VP & Pres. OSI Prosidion
Transactions
- Award
Stock Option (Right to Buy)
2009-12-15+20,000→ 20,000 totalExercise: $35.40From: 2010-12-15Exp: 2019-12-14→ Common Stock (20,000 underlying) - Tax Payment
Common Stock
2009-12-16$32.89/sh−949$31,213→ 31,623 total - Award
Common Stock
2009-12-15+6,700→ 32,572 total
Footnotes (4)
- [F1]Represents the Restricted Stock Unit component of the annual equity compensation to executive officers. 25% of the Restricted Stock Units vest one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years. The Reporting Person will receive one share of OSI Common Stock upon the vesting of each Restricted Stock Unit.
- [F2]Reflects the withholding of shares by the Company to satisfy the tax liability upon the vesting of Restricted Stock Units.
- [F3]25% of the option will become exerciseable one year after the date of grant and the remainder will vest ratably on an annual basis over the succeeding 3 years.
- [F4]Includes only options with the same termination date.